AIM ImmunoTech says Phase 2 DURIPANC pancreatic cancer trial advances toward Q1 2027 topline data

Bitget2026/10/01 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AIM ImmunoTech highlighted progress in its Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
Final Ampligen dosing is complete; topline results will be presented in the first quarter of 2027.
Interim updates pointed to immune activation signals; treatment has been well-tolerated with patients reporting high quality of life.
Separate Netherlands named-patient program data in post-FOLFIRINOX maintenance suggested encouraging survival, safety, and quality-of-life outcomes.
Management positioned upcoming DURIPANC results, including exploratory biomarkers, as input for designing a planned pivotal trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010902PRIMZONEFULLFEED9837819) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AIM ImmunoTech says Phase 2 DURIPANC pancreatic cancer trial advances toward Q1 2027 topline data

You may also like

Crypto prices